SCHEMBL3380438

SCHEMBL3380438

Fc1ccccc1-c1cc(-c2c[nH]c3nccnc23)c2cccnc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 2/20 0.47
CDK1 P06493 2/20 0.47
CCNB1 P14635 2/20 0.47
CCNB3 Q8WWL7 2/20 0.47
RET P07949 1/20 0.47
F2 P00734 1/20 0.42
F10 P00742 1/20 0.42
F7 P08709 1/20 0.42
F3 P13726 1/20 0.42
CDC7 O00311 5/20 0.41
DBF4 Q9UBU7 3/20 0.41
MAP4K4 O95819 2/20 0.41
PIM1 P11309 2/20 0.41
PRKACA P17612 2/20 0.41
GSK3B P49841 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
CDK2 P24941 2/20 0.41
ROCK2 O75116 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3380579 0.78 F10 (0.44) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL3383739 0.74 F2 (0.50) F2F10F7F3CYP1A2
SCHEMBL246143 0.74 KDM4E (0.45) F2F10F7F3PIM1
SCHEMBL14877206 0.74 CDC7 (0.46) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL247583 0.74 NPC1 (0.44) F2F10F7F3PIM1
SCHEMBL3393479 0.74 IKBKE (0.50) F2F10F7F3PIM1
SCHEMBL21756190 0.73 FEN1 (0.44) F2F10F7F3PIM1
SCHEMBL3380583 0.73 F2 (0.42) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL2302917 0.73 NPC1 (0.46) F2F10F7F3PIM1
SCHEMBL21756136 0.73 F2 (0.50) F2F10F7F3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585461-B1 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2020-02-26 EP disclosed
EP-2585461-B1 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2020-02-26 EP disclosed
US-8791113-B2 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-8791113-B2 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-25 US disclosed
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-25 US disclosed
WO-2012000595-A1 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER TGFBR1, TAB1, TGFBR2 CCNB2 628/4885CDK1 54/4885CCNB1 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.